Posted on

Biomind Labs to Present at Benzinga Psychedelics Capital Conference in the U.S. on April 19th 2022

Biomind Labs to Present at Benzinga Psychedelics Capital Conference in the U.S. on April 19th 2022

March 30, 2022 07:25 AM Eastern Daylight Time

TORONTO–(BUSINESS WIRE)–Biomind Labs Inc. (“Biomind Labs” or the “Company”) (NEO: BMND) (OTC: BMNDF) (FSE: 3XI), a leading biotech company focused on innovation and research on endogenous tryptamines (biomolecules acting as psychoneuroplastogens) for the treatment of mental health disorders and beyond, is pleased to announce that CEO Alejandro Antalich and Scientific and Clinical Advisor Dr. Dráulio Barros de Araújo will present at “Benzinga Psychedelics Capital Conference” that will be held in Miami at the Fontainebleau on April 19th, 2022.

This conference brings together leaders of the biggest publicly-traded psychedelics companies with investors from across North America.

This is a great opportunity to get a comprehensive understanding of Biomind Labs’ diversified portfolio of molecules targeting specific indications and tailored drug delivery systems, as well as its robust intellectual property strategy and future plans. Also, this is a great opportunity to learn about the Company’s advances on strategic commercial arrangements, such as the commencement of a commercial clinical trial on its proprietary drug candidate BMND06, a novel formulation based on the psychedelic molecule mescaline.

Neuroscientist Dr. Araújo will be sharing a unique scientific approach to one of the most promising psychedelic molecules, N, N-dimethyltryptamine (“DMT”). The Company is currently conducting a second Phase II investigational new drug clinical trial with an inhaled formulation of DMT, the results of which may assist the Company in identifying the most effective method of administrating its DMT candidate in patients with depression.
About Biomind Labs Inc.

Biomind Labs is a biotech research and development company aimed at transforming biomedical sciences knowledge into novel pharmaceutical drugs and innovative nanotech delivery systems for a variety of psychiatric and neurological conditions. Through its acceleration platform, Biomind Labs is developing novel pharmaceutical formulations of the main psychedelic molecules, DMT, 5-MeO-DMT and mescaline for treating a wide range of therapeutic indications. Biomind Labs’ focus is to provide patients access to affordable and modern-day treatments.

Cautionary Note Regarding Forward-Looking Statements

This press release contains statements that constitute “forward-looking information” (“forward-looking information”) within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking information and are based on expectations, estimates and projections as at the date of this news release. Any statement that discusses predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking information. Forward-looking statements in this document include, among others, statements relating to the ability of the Company’s innovation and research on endogenous tryptamines to possibly treat mental health disorders and beyond, the results of the Company’s second Phase II investigational new drug clinical trial with an inhaled formulation of DMT, statements regarding the Company’s commercial clinical trial on its proprietary drug candidate BMND06, the Company’s ability to provide patients access to affordable and modern-day treatments, the Company’s development of novel pharmaceutical formulations from the main psychedelic molecules, DMT, 5-MeO-DMT and mescaline for treating a wide range of and other statements that are not historical facts.

By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors and risks include, among others: (a) the Company may require additional financing from time to time in order to continue its operations which may not be available when needed or on acceptable terms and conditions acceptable; (b) compliance with extensive government regulation; (c) domestic and foreign laws and regulations could adversely affect the Company’s business and results of operations; (d) the stock markets have experienced volatility that often has been unrelated to the performance of companies and these fluctuations may adversely affect the price of the Company’s securities, regardless of its operating peers; (e) adverse changes in the public perception of tryptamine-based treatments and psychedelic-based therapies; (f) the impact of COVID-19; and (g) general business, economic, competitive, political and social uncertainties. Accordingly, readers should not place undue reliance on the forward-looking information contained in this press release.

The Company makes no medical, treatment or health benefit claims about the Company’s proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding tryptamine-based treatments, psychedelic-based therapies or other psychedelic compounds. The efficacy of such products has not been confirmed by approved research. There is no assurance that the use of psychedelic tryptamines, tryptamine derivatives or other psychedelic compounds can diagnose, treat, cure or prevent any disease or condition. Vigorous scientific research and clinical trials are needed. The Company has not yet completed commercial clinical trials for the use of its proposed products. Any references to quality, consistency, efficacy and safety of potential products do not imply that the Company verified such in commercial clinical trials or that the Company will complete such trials. If the Company cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on the Company’s performance and operations.

The forward-looking information contained in this news release represents the expectations of the Company as of the date of this news release and, accordingly, is subject to change after such date. Readers should not place undue importance on forward-looking information and should not rely upon this information as of any other date. The Company undertakes no obligation to update these forward-looking statements in the event that management’s beliefs, estimates or opinions, or other factors, should change.

Posted on

Wesana Health CEO Daniel Carcillo to Speak at Several Leading Investor and Industry Events

Wesana Health CEO Daniel Carcillo to Speak at Several Leading Investor and Industry Events

CHICAGO and TORONTO, March 29, 2022 (GLOBE NEWSWIRE) — Wesana Health Holdings Inc. (“Wesana” or the “Company”) (CSE: WESA; OTCQB: WSNAF), a data-driven life sciences company focused on developing the novel therapies of tomorrow and delivering new care paradigms today, is pleased to confirm CEO Daniel Carcillo will be speaking at several investor and industry events over the coming weeks.

Mr. Carcillo will be speaking at:

Benzinga Psychedelics Capital Conference, Miami, April 19

Noble Capital Markets’ NobleCon 18, Miami, April 19-21

The Psychedelic Therapeutics & Drug Development Conference, Washington, DC, May 23-24

“We are excited to update investors regarding Wesana’s most recent interactions with the FDA. Connecting with key stakeholders and community members about our novel drug development program and the defined pathway forward to regulatory approval is incredibly important to us,” said Mr. Carcillo.

To find out more or to arrange a meeting with Mr. Carcillo, please contact Keenan Gentry, Vice President Investor Relations & Corporate Development at Wesana via email, at IR@wesanahealth.com.

About Wesana Health

Wesana Health helps people transcend barriers in mental health and performance. We innovate in care development through our therapies and patent-pending protocols, and in care delivery through activating a new multidisciplinary, technology-supported clinical model. Learn more at www.wesanahealth.com.

Investor Relations:
Keenan Gentry
Email: IR@wesanahealth.com
Phone: 702-329-8038

Media Contacts:
Isadora Forman
Email: media@wesanahealth.com 
Phone: 917-653-4613

Primary Logo

Source: Wesana Health

Released March 29, 2022

Posted on

Universal Ibogaine To Participate In The 2022 Virtual Growth Conference

Universal Ibogaine To Participate In The 2022 Virtual Growth Conference

Presented by Maxim Group LLC and hosted by M-Vest on

March 28th – 30th from 9:00 a.m. – 5:00 p.m. EDT

Calgary, Canada – March 24, 2022 — [Universal Ibogaine] [TSXV:IBO and OTCQB:IBOGF], a life sciences company with a mission to transform the world of addiction treatment through medicalized ibogaine and a state of the art ongoing care program, announced today that Company CEO Nick Karos has been invited to present at the 2022 Virtual Growth Conference, presented by Maxim Group LLC and hosted by M-Vest, on March 28th – 30th   from 9:00 a.m. – 5:00 p.m. EDT.

Sign up here to access the presentation

During this virtual conference, investors will hear from executives from a wide range of sectors including Biotech, Clean Energy, Electric Vehicles, Financial Services, Fintech & REITS, Gaming & Entertainment, Healthcare, Healthcare IT, Infrastructure, Shipping and Technology/ Media/Telecom. The conference will feature company presentations, fireside chats, roundtable discussions, and live Q&A with CEOs moderated by Maxim Research Analysts.

This conference will be live on M-Vest. To attend, just sign up to become an M-Vest member.

Click Here to Reserve your seat

About Universal Ibogaine Inc. 

UI is a life sciences company, with a mission to demonstrate the safety and efficacy of its ibogaine based drug detox protocol through a planned Canadian Clinical Trial, and ultimately to utilize that protocol globally through future licensing agreements.  UI is concurrently developing a state-of-the-art holistic addiction treatment protocol at its Kelburn Recovery Centre in Winnipeg, Manitoba that, when paired with the planned ibogaine detox protocol, is intended to revolutionize the way we treat addiction and drastically improve the lives of individuals and families affected by addiction.

NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.  

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS  

‎This news release may contain forward-looking statements and information. Forward-looking information is frequently characterized by words such ‎as “plans”, “expect”, “project”, “intend”, “will”, “believe”, “anticipate”, “estimate”, “scheduled”, ‎‎”potential”, or other similar words, or statements that certain events or conditions “may”, “should” or ‎‎”could” occur.  The forward-looking statements and information are based on certain key expectations ‎and assumptions made by UI.  Although UI believes that the expectations and assumptions on which the forward-‎looking statements are based are reasonable, undue reliance should not be placed on the forward-‎looking statements because UI can give no assurance that they will prove to be correct.  

Since ‎forward-looking statements address future events and conditions, by their very nature they involve ‎inherent risks and uncertainties. Actual results could differ materially from those currently anticipated ‎due to a number of factors and risks, which include, but are not limited to, risks that required ‎regulatory approvals are not obtained. The reader is cautioned that assumptions used in the ‎preparation of such information, although considered reasonable by UI at the time of ‎preparation, may prove to be incorrect and readers are cautioned not to place undue reliance on ‎forward-looking information, which speaks only to conditions as of the date hereof.  UI does not ‎undertake any obligation to release publicly any revisions to forward-looking information contained ‎herein to reflect events or circumstances that occur after the date hereof or to reflect the occurrence ‎of unanticipated events, except as may be required under applicable securities laws. ‎ 

For further information:  

Investor Relations: Dugan Selkirk, IR Manager dugan.selkirk@universalibogaine.com

Chief Executive Officer:  Nick Karos, CEO nick.karos@admin_universalibogaine

Posted on

Delic Corp to Share Details of New Revenue Lines, Improved Outlook at Three Spring 2022 Investor Conferences

Delic Corp to Share Details of New Revenue Lines, Improved Outlook at Three Spring 2022 Investor Conferences

Matt Stang, Co-founder and CEO of Delic Corp, will outline the Company’s strategic outlook for the remainder of the year at the Scottsdale Capital Event on April 22-24, Planet MicroCap Showcase on May 4, H.C. Wainwright Annual Global Life Sciences Conference on May 23-26

VANCOUVER, BRITISH COLUMBIA, Mar. 23, 2022 – Delic Holdings Corp (“Delic” or the “Company”) (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, today unveiled details regarding Matt Stang, Co-founder and CEO of Delic, and his participation at the following events: Scottsdale Capital Event, Planet MicroCap Showcase and H.C. Wainwright Annual Global Life Sciences Conference.

  • Scottsdale Capital Event
    April 22-24, 2022
    Hosted by Capital Event Management in Arizona, the 8th Annual Scottsdale Capital Event will connect growing companies with premier financiers through scheduled Meetings and networking opportunities. During this event, Stang will participate in one-on-one meetings that examine the Company’s strategic outlook for the remainder of the year. To learn more about the Scottsdale Capital Event, visit https://cem.ca/conference/scottsdale-capital-event-2022/.
  • Planet MicroCap Showcase
    May 4, 2022
    At the premier in-person event in MicroCap Finance, Stang will give a presentation focused on Delic’s business expectations and growth opportunities for the second half of the year. The three-day event will also feature one-on-one meetings and educational panels. For more information about the Planet Microcap Showcase and complimentary registration, please visit https://planetmicrocapshowcase.com/
  • H.C. Wainwright Annual Global Life Sciences Conference
    May 23-26, 2022
    Located in the vibrant city of Miami, Florida, the H.C. Wainwright Annual Global Life Sciences Conference is a four-day event complete with fireside discussions, meetings with H.C. Wainwright Annual Global Life. Stang will not only present on the Company’s expansion strategy and industry outlook, but he will also participate in one-on-one meetings. For those unable to attend this year’s conference, his presentation will be available beginning June 10 at 7 a.m. EST. To register for this year’s conference, please visit https://hcwevents.com/globalconference/.

About Delic Corp

Delic is a leader in new medicines and treatments for a modern world, improving access to health benefits across the country and reframing the conversation on psychedelics. The company owns and operates an umbrella of related businesses, including the largest chain of psychedelic wellness clinics in the country, Ketamine Wellness Centers; the only licensed entity by Health Canada to exclusively focus on research and development of psilocybin vaporization technology, Delic Labs; the premier psychedelic wellness event, Meet Delic; and trusted media and e-commerce platforms Reality Sandwich and Delic Radio. Delic is backed by a team of industry and cannabis veterans and a diverse network, whose mission is to provide education, research, high-quality products, and effective treatment options to the masses.

The Canadian Securities Exchange ‎has neither approved nor disapproved the contents of this news release and does not accept responsibility ‎for the adequacy or accuracy of this release.‎

This news release does not constitute an offer to sell, or a solicitation of an offer to buy, any securities ‎in the United States. The securities have not been and will not be registered ‎under the United States ‎Securities Act of 1933, as amended (the “U.S. Securities Act“), or any state ‎securities laws and may not be offered or ‎sold within the United States unless registered under the U.S. ‎Securities Act and applicable state securities laws or an ‎exemption from such registration is available.‎

Forward-Looking Information and Statements

This press release contains certain “forward-looking information” within the meaning of applicable ‎Canadian securities ‎legislation and may also contain statements that may constitute “forward-looking ‎statements” within the meaning of ‎the safe harbor provisions of the United States Private Securities ‎Litigation Reform Act of 1995. Such forward-looking ‎information and forward-looking statements are not ‎representative of historical facts or information or current ‎condition, but instead represent only the ‎Company’s beliefs regarding future events, plans or objectives, many of ‎which, by their nature, are ‎inherently uncertain and outside of Delic’s control. Generally, such forward-looking ‎information or ‎forward-looking statements can be identified by the use of forward-looking terminology such as ‎‎”plans”, ‎‎”expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, ‎‎‎”anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or may ‎contain ‎statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be ‎taken”, “will continue”, ‎‎”will occur” or “will be achieved”. The forward-looking information and forward-‎looking statements contained herein ‎may include, but are not limited to: information regarding the timing or terms upon which the Transaction will be completed; potential benefits of the Transaction;  anticipated continued growth in the health and wellness sector (and, in particular, related to psychedelics); the ability of Delic to successfully achieve business ‎objectives, ‎and expectations ‎for other economic, ‎business, and/or competitive factors.‎

By identifying such information and statements in this manner, Delic is alerting the reader that ‎such ‎information and statements are subject to known and unknown risks, uncertainties and other factors ‎that may cause ‎the actual results, level of activity, performance or achievements of Delic to be ‎materially different from those ‎expressed or implied by such information and statements. Such risks and other factors may include, but are not limited to: risks and uncertainties relating to the Transaction not closing as planned or at all or on terms and conditions set forth in the Merger Agreement; incorrect assessment of the value and potential benefits of the Transaction; direct and indirect material adverse effects from the COVID-19 pandemic; inability to obtain future financing on suitable terms; failure to obtain required regulatory and other approvals; risks inherent in the psychedelic treatment sector; changes in applicable laws and regulations; and failure to comply with applicable laws and regulations.

In addition, in ‎connection with the forward-looking ‎information and forward-looking statements contained in this press ‎release, Delic has made certain ‎assumptions. These assumptions include, but are not limited to: assumptions as to the time required to negotiate a definite agreement and complete matters related to the Transaction; the ability to consummate the Transaction; ‎the ability of the parties to ‎obtain, in a timely manner, the requisite regulatory, corporate and other third party approvals and the satisfaction of ‎other conditions to the ‎consummation of the Transaction on the proposed terms; the potential impact of the announcement or consummation of the Transaction on ‎relationships, ‎including with regulatory bodies, employees, suppliers, customers and competitors; ‎changes in general economic, ‎business and political conditions, including changes in the financial ‎markets; changes in applicable laws; compliance ‎with extensive government regulation; and the diversion ‎of management time on the Transaction.‎

Should one or more of these risks, uncertainties or other factors materialize, or should assumptions ‎underlying the ‎forward-looking information or statements prove incorrect, actual results may vary ‎materially from those described ‎herein as intended, planned, anticipated, believed, estimated or ‎expected.‎

Although Delic believes that the assumptions and factors used in preparing, and the expectations ‎contained ‎in, the forward-looking information and statements are reasonable, undue reliance should not ‎be placed on such ‎information and statements, and no assurance or guarantee can be given that such ‎forward-looking information and ‎statements will prove to be accurate, as actual results and future events ‎could differ materially from those anticipated ‎in such information and statements. The forward-looking ‎information and forward-looking statements contained in this ‎press release are made as of the date of ‎this press release, and Delic does not undertake to update any ‎forward-looking information ‎and/or forward-looking statements that are contained or referenced herein, except in ‎accordance with ‎applicable securities laws. All subsequent written and oral forward-looking information and ‎statements ‎attributable to Delic or persons acting on its behalf is expressly qualified in its entirety by this ‎‎notice.‎

Investor Relations Contact
Rich Rodriguez
rich@deliccorp.com

Media Contact
Phoebe Wilson
MATTIO Communications
delic@mattio.com

Posted on

Field Trip Health Ltd. to Participate in Maxim Group 2nd Annual Virtual Growth Conference

Field Trip Health Ltd. to Participate in Maxim Group 2nd Annual Virtual Growth Conference

TORONTO, March 23, 2022 (GLOBE NEWSWIRE) — Field Trip Health Ltd. (TSX: FTRP, FTRP.WT, Nasdaq: FTRP) (“Field Trip”), a global leader in the development and delivery of psychedelic therapies, announced today that management will present at the Maxim Group 2nd Annual Virtual Growth Conference, hosted by M-Vest, taking place March 28-30, 2022.

A recording of Field Trip’s presentation will be available to view on demand beginning at 9:00 a.m. ET on Monday, March 28th. To listen to the Field Trip presentation, please click here. To register for the conference , please click here.

For institutional investors interested in scheduling a meeting with Field Trip’s management team, please contact KCSA Strategic Communications at fieldtripIR@kcsa.com.

About Field Trip Health Ltd.

Field Trip is a global leader in the development and delivery of psychedelic therapies. With our Field Trip Discovery division leading the development of the next generation of psychedelic molecules and conducting advanced research on plant-based psychedelics and our Field Trip Health division building centers for psychedelic therapies opening across North America and Europe along with the digital and technological tools that will enable massive scale, we help people in need with a simple, evidence-based way to heal and heighten engagement with the world.

Learn more at https://www.meetfieldtrip.com, https://www.fieldtriphealth.com and https://www.fieldtriphealth.nl.

Follow us on Twitter and Instagram: @fieldtriphealth.

To receive company updates about Field Trip and to be added to the email distribution list please sign up here.

Cautionary Note Regarding Forward-Looking Information  

This release includes forward-looking information (within the meaning of Canadian securities laws and within the meaning of the United States Private Securities Litigation Reform Act of 1995) regarding Field Trip and its business. Often but not always, forward-looking information can be identified by the use of words such as “expect”, “intends”, “anticipated”, “believes” or variations (including negative variations) of such words and phrases, or state that certain actions, events or results “may”, “could”, “would” or “will” be taken, occur or be achieved. Such statements are based on the current expectations and views of future events of the management of Field Trip and are based on assumptions and subject to risks and uncertainties. Although the management of Field Trip believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this release may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting the companies. Although Field Trip has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements or information. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Field Trip does not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. Additional information relating to Field Trip, including its Annual Information Form, can be located on the SEDAR website at www.sedar.com and on the EDGAR section of the SEC’s website at www.sec.gov.

This press release does not constitute an offer to sell or the solicitation of an offer to buy securities.

Neither the Toronto Stock Exchange, nor its Regulation Services Provider, have approved the contents of this release or accept responsibility for the adequacy or accuracy of this release.

CONTACTS:
Investor contacts:
KCSA Strategic Communications
fieldtripIR@kcsa.com

Media contacts:
Rachel Moskowitz
Autumn Communications
202-276-7881
press@fieldtriphealth.com

Posted on

Lobe Sciences Ltd. to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and Hosted by M-Vest on March 28th – 30th from 9:00 A.M. – 5:00 P.M. EDT

Lobe Sciences Ltd. to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and Hosted by M-Vest on March 28th – 30th from 9:00 A.M. – 5:00 P.M. EDT

Vancouver, British Columbia–(Newsfile Corp. – March 23, 2022) – Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) (“Lobe” or the “Company“) announced today that Philip Young, CEO, has been invited to present at the 2022 Virtual Growth Conference, presented by Maxim Group LLC and hosted by M-Vest, on March 28th – 30th from 9:00 a.m. – 5:00 p.m. EDT.

Sign up here to access the presentation

During this virtual conference, investors will hear from executives from a wide range of sectors including Biotech, Clean Energy, Electric Vehicles, Financial Services, Fintech & REITS, Gaming & Entertainment, Healthcare, Healthcare IT, Infrastructure, Shipping and Technology/ Media/Telecom. The conference will feature company presentations, fireside chats, roundtable discussions, and live Q&A with CEOs moderated by Maxim Research Analysts.

This conference will be live on M-Vest. To attend, just sign up to become an M-Vest member.

Click Here to Reserve your seat

* * *

About Lobe Sciences Ltd.

Lobe Sciences is a life sciences company focused on psychedelic medicines. The Company, through collaborations with industry-leading partners, is engaged in drug research and development using psychedelic compounds and the development of innovative devices and delivery mechanisms to improve mental health and wellness.

For further information please contact:

Lobe Sciences Ltd.
Philip J Young, CEO
info@lobesciences.com
Tel: (949) 505-5623

THE CSE HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS RELEASE.

Disclaimer for Forward-Looking Statements

This news release contains forward-looking statements relating to the future operations of the Company and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact included in this release, including statements regarding the future plans and objectives of the Company, research and development using psychedelic compounds, and the development of innovative devices and delivery mechanisms to improve mental health and wellness, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. Readers are cautioned that assumptions used in the preparation of the forward-looking statements may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company, including changes to the regulatory environment;, that the Company’s drug research and development activities may be unsuccessful; that drugs and medical devices produced by, or on behalf of, the Company, may not work in the manner intended or at all, and may subject the Company to product liability or other liability claims; that the Company may not be able to attain the Company’s corporate goals and objectives; and other risk factors detailed in the Company’s continuous disclosure filings from time to time, as available under the Company’s profile at www.sedar.com. As a result, the Company cannot guarantee that any forward-looking statement will materialize and the reader is cautioned not to place undue reliance on any forward-looking information. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made only as of the date of this news release and the Company does not intend to update any of the included forward-looking statements except as expressly required by applicable Canadian securities laws.

Posted on

PsyBio Therapeutics to Participate in the 2022 Maxim Group Virtual Growth Conference on March 28-30, 2022

PsyBio Therapeutics to Participate in the 2022 Maxim Group Virtual Growth Conference on March 28-30, 2022

PsyBio Therapeutics to Participate in the 2022 Maxim Group Virtual Growth Conference on March 28-30, 2022

OXFORD, Ohio and COCONUT CREEK, Fla., March 23, 2022 /CNW/ – PsyBio Therapeutics Corp. (TSXV: PSYB) (OTCQB: PSYBF) (“PsyBio” or the “Company“), an integrated and intellectual property driven biotechnology company focusing on discovering developing novel, bespoke psychoactive medicinal candidates targeting the potential treatment of mental health challenges, neurological disorders and other human health conditions, today announces that Evan Levine, Chief Executive Officer and Chairman, will participate in the 2022 Maxim Group Virtual Growth Conference on March 28-30, 2022.

PsyBio’s presentation will be available to view on demand beginning at 9:00 a.m. ET on Monday, March 28th. To attend, please register here. To listen to the presentation, please click here to access the webcast.

To schedule a meeting with the PsyBio management team, please contact KCSA Strategic Communications by emailing PsyBio@kcsa.com.

About PsyBio Therapeutics Corp.

PsyBio Therapeutics is fully integrated and intellectual property driven biotechnology company developing novel psychoactive medicinal candidates produced by genetically modified organisms targeting the potential treatment of mental health challenges, neurological disorders, and other human health conditions. The team has extensive experience in drug discovery based on synthetic biology and metabolic engineering as well as clinical and regulatory expertise progressing drugs through human studies and regulatory protocols. Research and development activities are currently ongoing for naturally occurring psychoactive tryptamines originally discovered in different varieties of hallucinogenic mushrooms, other tryptamines and phenethylamines and combinations thereof. The Company utilizes a bio-medicinal chemistry approach to therapeutic development, in which psycho-targeted compounds can be utilized as a template upon which to develop precursors and analogs, both naturally and non-naturally occurring, specifically because they are already known to have an effect within the brain.

PsyBio makes no medical, treatment or health benefit claims about PsyBio’s proposed products. The U.S. Food and Drug Administration (“FDA“) or other similar regulatory authorities have not evaluated claims regarding psilocybin and other next generation psychoactive compounds. The efficacy of such products has not been confirmed by FDA-approved research. There is no assurance that the use of psilocybin and other psychoactive compounds can diagnose, treat, cure, or prevent any disease or condition. Vigorous scientific research and clinical trials are needed. PsyBio has not conducted clinical trials for the use of its intellectual property. Any references to quality, consistency, efficacy and safety of potential products do not imply that PsyBio verified such in clinical trials or that PsyBio will complete such trials. If PsyBio cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on the PsyBio’s performance and operations.

The TSX Venture Exchange (“TSXV“) has neither approved nor disapproved the contents of this news release. Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.

SOURCE PsyBio Therapeutics Corp.

Posted on

atai Life Sciences to Participate in Upcoming March Investor Conferences

atai Life Sciences to Participate in Upcoming March Investor Conferences

NEW YORK, March 21, 2022 (GLOBE NEWSWIRE) — atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the following upcoming investor conferences in March:

  • Citi Winter Biotech Virtual Bus Tour
    Format: Fireside Chat – Virtual
    Date and Time: Tuesday, March 22nd, 11:00 a.m. ET – 11:40 a.m. ET
    Conference Link: URL
  • Maxim Group 2022 Virtual Growth Conference
    Format: Company Presentation – Virtual
    Date and Time: Monday, March 28th, 2022 – Wednesday, March 30th, 2022
    Conference Link: URL

The presentations and archived webcasts will also be accessible in the Events section of atai’s website.

About atai Life Sciences

atai is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. atai was founded in 2018 as a response to the significant unmet need and lack of innovation in the mental health treatment landscape. atai is dedicated to acquiring, incubating and efficiently developing innovative therapeutics to treat depression, anxiety, addiction, and other mental health disorders.

atai’s business model combines funding, technology, scientific and regulatory expertise with a focus on psychedelic therapy and other drugs with differentiated safety profiles and therapeutic potential. By pooling resources and best practices, atai aims to responsibly accelerate the development of new medicines across its companies, seeking to effectively treat and ultimately heal mental health disorders.

atai’s vision is to heal mental health disorders so that everyone, everywhere can live a more fulfilled life. atai has offices in New York, London, and Berlin. For more information, please visit www.atai.life.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any express or implied statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are neither promises nor guarantees, but involve known and unknown risks and uncertainties that could cause actual results to differ materially from those projected, including, without limitation, the important factors discussed under the caption “Risk Factors” in atai’s prospectus pursuant to Rule 424(b) filed with the U.S. Securities and Exchange Commission (“SEC”) on June 21, 2021, as such factors may be updated from time to time in atai’s other filings with the SEC. atai disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release, other than to the extent required by applicable law.

Contact Information

Investor Contact:
Greg Weaver
Chief Financial Officer, atai Life Sciences
Email: greg.weaver@atai.life

Media Contact:
Camilla Dormer
VP, Communications, atai Life Sciences
Email: camilla@atai.life

Posted on

Cybin to Participate in the 2022 Maxim Group Virtual Growth Conference on March 28-30, 2022

Cybin to Participate in the 2022 Maxim Group Virtual Growth Conference on March 28-30, 2022

TORONTO–(BUSINESS WIRE)– Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company”), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics™” is pleased to announce that Doug Drysdale, Cybin’s Chief Executive Officer, will present at the 2022 Virtual Growth Conference, presented by Maxim Group LLC and hosted by M-Vest, taking place March 28th – 30th from 9:00 a.m. – 5:00 p.m. ET.

Mr. Drysdale’s presentation will be available on demand beginning at 9:00 a.m. ET on Monday, March 28th. To attend, please register here to access the conference. To listen to the presentation, please click here to access the webcast. The archived webcast will also be available on the Company’s investor relations website on the Events & Presentations page.

About Cybin
Cybin is a leading ethical biopharmaceutical company, working with a network of world-class partners and internationally recognized scientists, on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues. Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, United Kingdom and Ireland. The Company is focused on progressing Psychedelics to Therapeutics by engineering proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health disorders.

Investor & Media:

Leah Gibson
Vice President, Investor Relations
Cybin Inc.
leah@cybin.com

Source: Cybin Inc.

Posted on

M2Bio Sciences Attending Master Investor Show in London, UK

M2Bio Sciences Attending Master Investor Show in London, UK

CAPE TOWN, SA / ACCESSWIRE / March 16, 2022 / WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) (“WGG” or the “Company”), a bioceutical company focused on alternative plant-based cannabinoids and mental health therapeutic research is pleased to share the following update:

M2Bio Sciences is pleased to announce that CEO Jeff Robinson and Chief Medical Officer Dr. Anna Morera Leralta will be attending the Master Investor Show in London, UK at the Business Design Centre, Saturday, 19 March 2022.

The event will host approximately 5000 attendees throughout the day and feature investment categories ranging from biotechnology, longevity, regenerative medicine, AI, blockchain, agronomics and many more. The show will also feature the latest insights from well-known personalities in the UK investment industry. Jeff Robinson and Dr. Anna Morera Leralta will meet with retail and institutional investors, academics and speakers Jim Mellon, with whom Dr. Anna Morera Leralta completed an internship in London in 2016 and Dr. Greg Bailey of Juvenescence.

“Both Dr. Anna and I are very excited to attend our fifth Master Investor Show. Expanding our knowledge base and networking is so very important, not to mention being able to attend an event in person finally! We would like to extend an invitation to all our friends in London to join us and meet up for a coffee.” said Jeff Robinson – CEO

Jeff is currently in London (March 16 – March 22) and can be reached at jeff@m2bio.co

Master Investor annually host their flagship event, ‘The Master Investor Show’, introducing private investors to a day filled with networking opportunities, presentations and professional guidance from the leading companies and best experts within the financial and investment sectors. Covering various industries, this event caters to a wide audience and is definitely not one to be missed.

Master Investor Show also provides access to the broadest spectrum of investment opportunities to be found; from Trusts and Funds to Small Cap Companies and beyond to Start-Ups in the early stages of fund raising. Meet and hear from experts about what they are investing in and why.

You can get tickets here or if you can’t make it it can be viewed via livestream here.

About Wuhan General Group, Inc./ M2Bio Sciences, Inc

Wuhan General Group, Inc. (DBA M2bio Sciences), through its wholly-owned subsidiary MJ MedTech is a nutraceutical biotechnology company focused on alternative plant-based cannabinoids and psilocybin medical research that develops and commercializes a range of CBD and mushrooms-based products under Dr. AnnaRx™, Medspresso™, and Liviana™ brands. In addition, our research and clinical trials with psilocybin are aimed at new therapies that will help patients who suffer from alcohol addiction, mental illness, and cardiovascular diseases. Our mission is to advance botanical-based medicine to the forefront by deploying best-practice science and medicine, clinical research, and emerging technologies. The Company is traded on the Over-the-Counter Bulletin Board of NASDAQ under the trading symbol “WUHN”.

Publicly traded company (OTC Pink: WUHN)
Visit Website
Contact via E-mail
Follow us on Twitter
Follow us on Facebook
Follow us on YouTube
Follow us on Instagram

Forward-Looking Statements:

Safe Harbour Statement – In addition to historical information, this press release may contain statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief, or expectations of the Company and members of its management team with respect to the Company’s future business operations and the assumptions upon which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and involve risks and uncertainties and that actual results may differ materially from those contemplated by such forward-looking statements. Factors that could cause these differences include, but are not limited to, failure to complete anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance, efficiency and profitability, and adverse developments with respect to litigation or increased litigation costs, the operation or performance of the Company’s business units or the market price of its common stock. Additional factors that could cause actual results to differ materially from those contemplated within this press release can also be found on the Company’s website. The Company disclaims any responsibility to update any forward-looking statements.

SOURCE: Wuhan General Group, Inc./ M2Bio Sciences, Inc.

View source version on accesswire.com:
https://www.accesswire.com/693318/M2Bio-Sciences-Attending-Master-Investor-Show-in-London-UK